Our Mission
CardioNova Therapeutics exists to transform the lives of people with structural heart disease. From pioneering transcatheter valve technologies to developing the next generation of surgical repair products, everything we do is guided by the patients who depend on our innovations.
We invest more than 15% of revenue in R&D each year, maintain operations in over 100 countries, and treat more than 2 million patients annually — all in service of a single goal: helping people live longer, healthier lives.
Science-Driven Innovation
We invest more than 15% of revenue in R&D each year — developing breakthrough technologies that address unmet clinical needs in structural heart disease.
Patient-Centered Purpose
Every product decision, every clinical trial, every training program begins and ends with one question: will this help patients live longer, healthier lives?
Global Reach
With operations in over 100 countries and products reaching more than 2 million patients annually, our global footprint ensures our innovations reach those who need them most.
Our History
Five decades of firsts — from the ball-and-cage valve to the world's most implanted transcatheter heart valve.
Founded
CardioNova Therapeutics was founded by Dr. Marcus R. Hale in Irvine, California, with a mission to develop superior heart valve prostheses.
First Porcine Bioprosthesis
CardioNova introduced its first porcine tissue valve — a major advance in bioprosthetic valve technology that reduced thromboembolic risk.
Resilia™ Technology Inception
Our scientists begin development of the proprietary dual-fixation chemistry that would become Resilia™ — a 15-year research journey to eliminate calcification.
First TAVR Program
CardioNova receives first regulatory approval for its transcatheter aortic valve replacement program in Europe, beginning a new era in structural heart care.
NovaCor™ FDA Approval
FDA approves the NovaCor™ TAVR system for high-risk and inoperable patients — the beginning of U.S. commercial TAVR expansion.
Resilia™ Valve Commercial Launch
The NovaResilience™ Aortic Valve with Resilia™ tissue receives FDA clearance and reaches its 100,000th implant within 24 months of launch.
Expanding the Frontiers
CardioNova now leads clinical programs in transcatheter mitral and tricuspid repair, next-generation TAVR, and hemodynamic monitoring — expanding our impact across all four heart valves.
Leadership Team
Our leadership combines deep medical device expertise with clinical insight and a relentless commitment to patients.
Dr. Michael R. Chen
President & Chief Executive Officer
Dr. Chen joined CardioNova in 2012 and was appointed CEO in 2018. He holds an MD from Johns Hopkins and an MBA from Wharton.
Sarah L. Martinez
Chief Financial Officer
Ms. Martinez brings 25 years of financial leadership in the medtech sector. Previously CFO at two Fortune 500 medical device companies.
Dr. James K. Oduya
Chief Scientific Officer
Dr. Oduya leads our global R&D organization and is the principal inventor of Resilia™ tissue technology. Holds 47 patents in cardiac devices.
Innovation at Our Core
CardioNova's R&D organization employs over 2,000 scientists, engineers, and clinicians across eight global innovation centers.
Our pipeline spans early-stage biomaterial research through late-stage pivotal clinical trials — with over 30 active clinical programs currently enrolling patients worldwide. We partner with leading academic medical centers and patient advocacy organizations to ensure our research agenda reflects true unmet clinical need.
Sustainability & Responsibility
We believe that leading in healthcare innovation also means leading in environmental stewardship, ethical governance, and community impact.
Environmental Commitment
CardioNova has committed to net-zero greenhouse gas emissions by 2035. Our manufacturing facilities in California and Ireland operate on 100% renewable electricity.
Global Access Programs
Through our CardioAccess program, we partner with ministries of health and NGOs to expand access to heart valve therapies in low- and middle-income countries.
Ethical Supply Chain
All CardioNova suppliers are required to meet our Supplier Code of Conduct, which covers labor rights, environmental standards, and anti-corruption practices.